No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 61,456 | 59,140 | 62,672 | 65,081 | 63,118 | 73,255 | 82,886 | 82,886 |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 2,014 | 2,563 | 2,492 | -407 | 1,174 | 2,585 | 6,169 | 6,169 |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Headquartered in Kyoto, Japan, DKS Co. Ltd. is a global producer and purveyor of a diverse range of industrial chemicals and surfactants, serving numerous industries worldwide. The company’s operations are organized into six distinct segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. Within its Surfactants division, DKS develops various types such as nonionic, anionic, cationic, polymerizable, and amphoteric compounds, in addition to specialized surfactant blends. The Amenity Materials segment features products like sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and other polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, and industrial deodorizers. Its Polyurethane Materials offerings include polyether polyols, urethane prepolymers, and comprehensive urethane systems. For Functional Materials, DKS manufactures radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants. The Electronic Device Materials group supplies ionic liquids, ion-conductive polymers, ceramic/metal injection molding components, conductive pastes for electronic applications, injection molding pellets, and advanced inorganic materials. Furthermore, the Life Sciences segment crafts health and dietary supplements, notably an I. Japonica-Bombyx Fungus product and Sudachin, a distinct citrus peel extract powder. Founded in 1909, the firm was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. before rebranding to DKS Co. Ltd. in 2013.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in Kyoto, Japan, DKS Co. Ltd. is a global producer and purveyor of a diverse range of industrial chemicals and surfactants, serving numerous industries worldwide. The company’s operations are organized into six distinct segments: Surfactants, Amenity Materials, Polyurethane Materials, Functional Materials, Electronic Device Materials, and Life Sciences. Within its Surfactants division, DKS develops various types such as nonionic, anionic, cationic, polymerizable, and amphoteric compounds, in addition to specialized surfactant blends. The Amenity Materials segment features products like sucrose fatty acid esters, sodium carboxymethyl celluloses, cellulose nanofibers and other polymers, polyvinyl pyrrolidone, polyacrylamide and polyacrylate, and industrial deodorizers. Its Polyurethane Materials offerings include polyether polyols, urethane prepolymers, and comprehensive urethane systems. For Functional Materials, DKS manufactures radiation-curable monomers and oligomers, waterborne polyurethanes, flame retardants, and amide-based lubricants. The Electronic Device Materials group supplies ionic liquids, ion-conductive polymers, ceramic/metal injection molding components, conductive pastes for electronic applications, injection molding pellets, and advanced inorganic materials. Furthermore, the Life Sciences segment crafts health and dietary supplements, notably an I. Japonica-Bombyx Fungus product and Sudachin, a distinct citrus peel extract powder. Founded in 1909, the firm was formerly known as Dai-ichi Kogyo Seiyaku Co., Ltd. before rebranding to DKS Co. Ltd. in 2013.